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arthritis (4–8). High levels of TNF also 
were detected in the wound fluid of 
chronic nonhealing wounds and induce 
cytotoxicity (9).
In many chronic inflammatory diseases, 
TNF inhibition results in the downreg-
ulation of abnormal and progressive 
inflammatory processes, induces rapid 
and sustained clinical remission, im-
proves quality of life and prevents target 
organ damage (10). It acts as a potent 
chemoattractant for neutrophils, induces 
microvascular leakage and promotes 
the expression of adhesion molecules 
on endothelial cells, helping neutrophils 
to migrate (11,12). Furthermore, TNF is 
upregulated in activated neutrophils and 
interacts both synergistically and an-
tagonistically with cytokines of the IL-6 
family (13). The subsequent development 
of biological agents capable of blocking 
TNF has led to important advances in 
the pharmacotherapy of such diseases 
correlate with the severity of infection 
(2,3). In accordance with this, TNF block-
ade has been shown to be an effective 
therapy in various immune-mediated 
inflammatory diseases, such as rheuma-
toid arthritis, psoriatic arthritis, plaque 
psoriasis, inflammatory bowel disease 
(i.e., Crohn’s disease, ulcerative colitis 
and intestinal Behçet’s disease), ankylos-
ing spondylitis, axial spondyloarthritis, 
systemic vasculitis and juvenile idiopathic 
iNTroDUCTioN
Tumor necrosis factor α (TNF) was 
originally described as a circulating 
factor that can cause necrosis of tumors, 
but has since also been identified as a 
key regulator of inflammatory responses 
(1). TNF is typically not detectable in the 
serum and tissue of healthy individuals; 
however, elevated serum and tissue 
levels are found in inflammatory and 
infectious conditions, and serum levels 
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and confirmed the concept of a common 
pathophysiology among immune-mediated 
inflammatory diseases, with TNF having 
a predominant role. Five TNF inhibitors 
have currently been approved for treat-
ment of 1 or more immune-mediated 
diseases: adalimumab, etanercept (ETA), 
golimumab, infliximab and certolizumab 
pegol (6). Because of the role of TNF 
blockade in many inflammatory diseases, 
we evaluated its contribution to another 
immune-mediated inflammatory disease, 
epidermolysis bullosa acquisita (EBA), a 
prototypic antibody-dependent and or-
gan-specific autoimmune blistering skin 
disease (AIBD) (14–17).
The pathogenic relevance of autoanti-
bodies in EBA has been clearly demon-
strated (18,19). These autoantibodies are 
directed against type VII collagen (COL7), 
a major component of anchoring fibrils. 
After binding to its target in the skin, a 
proinflammatory milieu is generated. In 
different experimental models of EBA, it 
has been demonstrated that proinflam-
matory cytokines such as IL-1, granu-
locyte macrophage colony–stimulating 
factor (GM-CSF) and antiinflammatory 
cytokines such as IL-6 are involved in the 
pathogenesis of EBA (20,21). Together 
with complement activation (22), this 
milieu leads to neutrophil extravasation 
and activation (23) in an FcγR-dependent 
manner (24). Reactive oxygen species 
and proteolytic enzymes are released by 
neutrophils, resulting in subepidermal 
blister formation (23). Increased expres-
sion of TNF in skin and/or serum of 
AIBD patients has long been noted (25). 
Individual case reports show clinical  
remission of pemphigoid disease after 
second-line therapy with etanercept 
(26,27) and effects in patients with pem-
phigus vulgaris (PV) (28–31). Functional 
data demonstrated that after transfer of 
pemphigus patient serum into neonatal 
mice, TNFR1-/TNFR2-deficient mice 
developed fewer blisters than wild-type 
mice (32). In contrast, no data concerning 
the role of TNF in the pathogenesis of 
EBA have been published so far. There-
fore, we analyzed the effects of TNF block-
ade on the effector phase of this disease.
MATeriALs AND MeTHoDs
experiments with Human Biomaterial
For determination of TNF expression 
and cryosections assays, normal human 
skin as well as lesional and nonlesional 
skin from EBA and bullous pemphigoid 
(BP) patients was obtained. Diagnosis 
was established based on clinical pre-
sentation, detection of IgG and/or C3 
deposits in direct IF microscopy of per-
ilesional skin biopsies, detection of the 
corresponding circulating autoantibodies 
or detection of a u-serrated pattern in 
direct IF microscopy in the case of EBA 
patients. All experiments using human 
samples were approved by the local 
ethics committee (University of Lübeck, 
Germany, and University of Groningen, 
the Netherlands) and were performed 
according to the Declaration of Helsinki. 
Blood donors and patients provided 
written informed consent prior to study 
participation.
Animal experiments
C57BL/6J mice (Charles River) were 
used for the antibody transfer–induced 
EBA model with prophylactic applica-
tion of ETA and monoclonal antibody. 
B6.SJL-H2s C3c/1CyJ (B6.S) animals were 
provided by Jackson Laboratories and 
bred at the University of Lübeck, Germany. 
Mice were used for experimental EBA 
models at the age of 8 to 10 wks. Ani-
mal experiments were approved by local 
authorities of the Animal Care and Use 
Committee (Kiel, Germany) and performed 
by certified personnel.
induction of experimental eBA and BP
Antibody transfer–induced EBA: 
Rabbits were immunized with a frag-
ment of murine type VII collagen NC1 
(mCOL7C). IgG from immune serum 
was isolated as previously described 
(33). Mice were injected intraperitoneally 
(i.p.) 6× with 5 mg rabbit anti-mCOL7C 
IgG per mouse for 5 d consecutively. 
ETA (Enbrel) was administered i.p.  
(2.5 mg/kg body weight) 2 d prior  
to the initial anti-mCOL7C IgG injection 
and then every other day (7× total). 
Blocking monoclonal antibody to murine 
TNF (clone MP6-XT22, eBioscience) or iso-
type antibody (clone eBRG1, eBioscience) 
with a dose of 150 μg/mouse was injected 
i.p. every other day starting 2 d prior to the 
initial rabbit anti-mCOL7C IgG injection 
and stopping at d 8 (6× total).
Immunization-induced EBA: B6.S mice 
were immunized with 120 μg vWFA2 
domain of COL7 emulsified (1:2) in Titer-
Max as described previously, with minor 
modifications (34,35). Briefly, 60 μL of 
vWFA2/TiterMax emulsion was in-
jected into the foot pad of each hind leg. 
Starting 3 wks after immunization, mice 
were randomly allocated into either TNF 
blocking or solvent treatment groups if 
they presented erythema, blisters, ero-
sions, crust or alopecia on more than  
2% of their body surface area. Treatment 
was performed with ETA injected i.p. 
(2.5 mg/kg body weight) every other 
day for 6 wks. For clinical score, mice 
were examined once per week, and 
body surface areas affected by erythema, 
blisters, erosions, crust or alopecia were 
observed. Relative clinical scores were 
calculated by normalizing the weekly 
score to the initial clinical score when 
allocated into treatment groups (weekly 
clinical score/initial clinical score). 
Disease severity was defined as the in-
tegrated relative clinical score over time 
(area under the curve).
Local antibody transfer–induced BP: 
Rabbits were immunized with a frag-
ment of murine type XVII collagen and 
IgG from immune serum was isolated 
as previously described (36). Mice were 
injected once with 1 mg rabbit an-
ti-mCOL17 IgG per mouse into the ear 
base. ETA (Enbrel) was administered i.p. 
(2.5 mg/kg body weight) 2 d prior to the 
initial anti-mCOL7C IgG injection and 
then every day (4× total). Ear thickness 
and scoring were performed at d 2 after 
IgG injection.
Histopathology and Direct 
immunofluorescence staining
Biopsies of lesional and perilesional 
skin were obtained at d 12 of antibody 
transfer–induced EBA and prepared for 
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Human Monocytes and 
Polymorphonuclear Purification
Human polymorphonuclear (PMN) 
leukocytes and peripheral blood mono-
nuclear cells (PBMCs) were isolated 
from whole blood samples using the 
PolymorphPrep (Progen) gradient  
according to the manufacturer’s in-
structions. In the next step, human 
monocytes were purified from the iso-
lated PBMCs by the magnetic cell  
separation method using a Monocyte 
Isolation Kit II, human (Miltenyi),  
according to the manufacturer’s in-
structions. The purity of monocytes and 
neutrophils was evaluated by fluorescent 
staining with PE/Cy7 anti-human CD14 
antibody (clone HCD14, Biolegend) and 
fluorescein isothiocyanate anti-human 
CD16 antibody (BD Biosciences) in a 
flow cytometer (MACSQuant Analyzer 10, 
Miltenyi).
Human Cryosection Assay
Human breast skin biopsies from 
healthy donors were cut into 6 μm  
sections. The slides were incubated in a 
humidified air incubator containing  
5% CO2 (Memmert) for 1 h at 37°C with 
200 μg/mL anti-human Col7-IgA2 an-
tibody or 1 × PBS for the negative con-
trols. Cryosection assay was performed 
as previously described (38). In short, a 
chamber of approximately 0.3 mm thick-
ness and 0.25 mL volume was created by 
covering a slide containing the tissue sec-
tion with a second slide carrying trans-
parent adhesive tape around its ends 
and taping them together with Parafilm 
(Pechiney). Next, 5 × 106 monocytes or 
PMNs were added to the chamber at a 
final volume of 150 μL. After incubation 
for 2.5 h at 37°C, the chamber was disas-
sembled. A washing step with 1 × PBS 
for 15 min followed, and the sections 
were fixed in formalin and stained with 
hematoxylin and eosin. Images in bright-
field mode were captured using a Key-
ence BZ-9000 fluorescence microscope 
and BZ-II Viewer software (Keyence). 
The length of the split formation was 
assessed by 2 independent and blinded 
observers.
real-time PCr
Real-time PCR of skin sections was 
performed as previously described (37). 
RNA from lesional (n = 4) and nonle-
sional (n = 3) skin from corresponding 
anatomical sites was obtained using the 
innuPREP RNA Mini Kit (Analytik Jena). 
After reverse transcription, cDNA was 
added to the qPCR MasterMix Plus  
(Eurogentec) and amplified using an SDS 
ABI 7000 or SDS ABI 7900 system (Ap-
plied Biosystems). TaqMan probes and 
forward and reverse primers were de-
signed with CloneManager (SciEd);  
MLN-51 was used as a housekeeping 
gene. The primers used were mMLN-51for 
(5′ CCA AGC CAG CCT TCA TTC TTG), 
mMLN-51rev (5′ TAA CGC TTA GCT  
CGA CCA CTC TG), mTNFfor (5′ CCC  
TCA CAC TCA GAT CAT CTT CTC) and 
mTNFrev (5′ TGG CTC AGC CAC TCC AG).
Bio-Plex
On d 12 of antibody transfer–induced 
EBA, serum was obtained from the mice 
and analyzed for concentrations of cyto-
kines (TNF, IL-6, G-CSF and keratinocyte 
chemoattractant [KC]). This was per-
formed by a commercial supplier using 
the Bio-Plex system (Bioglobe GmbH).
reactive oxygen species release 
Assay
A Lumitrack high-binding 96-well 
plate (Thermo Fisher Scientific) was 
coated with immune complexes (ICs) 
consisting of human Col7E-F antigen at a 
final concentration of 2.5 μg/mL and  
anti-human Col7-IgG1 or anti-human 
Col7-IgA2 antibody at a final concentration 
of 1.8 μg/mL as described previously 
(38); 2 × 105 cells were added per well. 
As controls, antigens or antibodies alone 
were added to the wells. Just before mea-
surement, luminol (Sigma) was added to 
the wells and chemiluminescence result-
ing from reactive oxygen species (ROS) 
production was measured immediately 
in a luminescence reader (Wallac 1420 
Manager, Victor3). The ROS release  
was measured for 1 s per well 66× for a  
period of ~ 3 h at a constant temperature 
of 37°C (38).
examination by histopathology and IF 
microscopy, as described previously (33). 
In brief, the biopsies collected from mice 
were fixed in 4% phosphate-buffered 
saline (PBS) and buffered formalin, and 
subsequently sections from paraffin- 
embedded tissues were stained with  
hematoxylin and eosin. IgG and C3 depos-
its were detected by direct IF microscopy 
on frozen sections prepared from tissue 
biopsies using fluorescein isothiocyanate–
labeled antibodies specific to rabbit IgG 
(Dako) and murine C3 (MP Biomedicals).
immunohistochemistry and 
immunofluorescence
Immunohistochemical analysis was 
performed as previously described, with 
minor modifications (21). Monoclonal 
antibodies specific for murine TNF (clone 
MP6-XT22) were purchased from AbD 
Serotec, anti-human TNF antibody (clone 
52B83) was purchased from Abcam and 
isotype control (mouse reference serum) 
was purchased from Bethyl Laboratories. 
Rat monoclonal antibody (clone MOMA-2) 
for staining of intracellular antigen of 
mouse macrophages and monocytes was 
purchased from Acris Antibodies. Serial 
cryosections (6 μm) of organ tissue samples 
were fixed in absolute acetone for 10 min 
at 4°C and air-dried before blocking of 
nonspecific immunoreactive sites with 3% 
bovine serum albumin or 5% normal goat 
serum (Sigma) in PBS for 20 min at room 
temperature. The sections were subse-
quently incubated with primary antibodies 
at the appropriate dilution at 4°C over-
night. Staining was visualized by addition 
of secondary antibodies (peroxidase- 
conjugated goat anti-rat IgG, Dianova) 
and Histogreen Chromogen (Linaris), and 
the reaction was terminated by washing 
in tap water. Samples were counterstained 
with Meyer’s hematoxylin and mounted 
with Vectamount (Vector Laboratories). 
Alternatively, fluorescent-labeled sec-
ondary antibodies (Cy™3-conjugated 
goat anti-mouse IgG [H + L] polyclonal 
antibody, 1/100 in PBS-T, Jackson Labo-
ratories) were used and the sections were 
embedded using DAPI and Mowiol 4-88 
(Sigma).
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statistical Analysis
All data are presented as the mean ± 
standard error of the mean, unless oth-
erwise indicated. GraphPad Prism 5 and 
7 were used to determine significant 
differences. For comparison of differ-
ences between two groups, t test was 
used, and for analysis of more than two 
groups, one-way analysis of variance 
with Bonferroni post-test was applied. 
A p value < 0.05 was considered statisti-
cally significant.
resULTs
TNF Levels Are increased in the skin of 
experimental and Human AiBD
To investigate a possible effect of 
TNF during EBA and other AIBDs, we 
stained three human lesional and nonle-
sional skin specimens from EBA and BP 
patients and three normal human skin 
specimens using anti-TNF antibody. As 
expected, only inflamed regions (around 
the blister) showed clear staining for 
TNF, whereas normal human skin and 
nonlesional regions were negative for 
TNF (Figure 1A). To verify these find-
ings in experimental models of EBA, we 
performed repeated injections of rabbit 
anti-mCOL7C IgG in mice (39). To verify 
these findings in mouse models of AIBD, 
ear samples were collected from mice in-
jected with anti-mCOL7C IgG and with 
normal rabbit IgG 12 d after the first in-
jection. By immunohistochemistry stain-
ing of the ear skin with rat anti-mouse 
TNF antibody, we demonstrated in-
creased staining of TNF in skin lesions 
of diseased mice, while less staining was 
found in the control skin (Figures 1B, C). 
Furthermore, TNF mRNA expression 
in lesional skin of mice with antibody 
transfer–induced EBA was significantly 
increased compared to that in healthy 
skin from the same mice (p = 0.0382,  
Figure 1D). In contrast, the level of TNF 
in the serum of mice after antibody 
transfer–induced EBA was similar be-
tween mice that received pathogenic 
IgG and controls (p = 0.7075, Figure 1E). 
These data suggest that tissue-expressed 
TNF (especially in lesional skin) but not 
circulating TNF is increased in experi-
mental EBA and human AIBDs.
Prophylactic TNF inhibition reduces 
Blistering in Antibody Transfer-induced 
eBA and BP
Mice treated with TNF blocking  
antibody (TNF mAb) and subsequently 
injected with anti-mCOL7C IgG 
showed a significant difference regard-
ing disease progression at d 8 and  
12 when compared with mice treated 
with an isotype-control antibody 
(Figures 2A–D) (d 8, p = 0.029; d 12, 
p = 0.009). Immunohistochemistry 
staining revealed reduced monocytes/
macrophages (anti–MOMA-2) and TNF 
in lesional skin of the TNF mAb–treated 
group, while blister formation and  
IgG/C3 deposition at the dermal-epidermal 
junction were comparable in both groups 
(Figures 2F–O).
Currently, the contribution of mono-
cytes/macrophages to the development of 
skin lesions in EBA, in both patients and 
experimental models, has not been stud-
ied in detail. Here, we show that macro-
phages constitute a substantial percentage 
Figure 1. Tissue expression of TNF was increased in experimental EBA. (A) Immunofluores-
cence staining of skin obtained from human BP and EBA patients and normal human 
skin. Red color indicates the presence of TNF only in lesional skin from EBA or BP patients. 
Inlay: isotype control staining. Images shown are representative of three specimens 
investigated per group. (B,C) Immunohistochemistry staining of ear skin obtained from 
(B) an anti-mCOL7C IgG-injected mouse and (C) a normal rabbit IgG-injected control 
mouse (scale bar: 400 μM). Blue color indicates the presence of TNF. (D) Ear samples 
from lesional skin (lesion, n = 5) and healthy areas (healthy, n = 5) after antibody  
transfers of anti-mCOL7C IgG were analyzed for mRNA levels of TNF by real-time PCR  
(n = 5/group, *p = 0.0382). (E) TNF concentration was measured by Bio-Plex in the serum 
of antibody transfer–induced EBA (anti-mCOL7C IgG, n = 7) and normal rabbit  
IgG–injected animals (control IgG, n = 4) 12 d after the first IgG injection. No significant 
difference was observed between the two groups.
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with either isotype or ETA and TNF 
mAb. Although serum levels of TNF 
were unaltered in the TNF intervention 
groups compared with untreated mice 
(Figure 1A), levels of IL-6, G-CSF and 
KC were reduced after TNF inhibition 
(Figure 4). To verify the effect of TNF 
blockage in another mouse model for 
autoimmune blistering disease, we also 
injected mice with ETA and subse-
quently with anti-mCOL17 IgG as an 
experimental model for BP (40). Again, 
treatment with ETA showed a signifi-
cant difference regarding disease pro-
gression at d 2 (p = 0.04) (Figures 2F–G).
Therapeutic Treatment with eTA 
Diminishes the extent of Blistering in 
immunization-induced eBA
We next evaluated the therapeutic 
potential of ETA in mice with already 
established clinical EBA. B6.S mice were 
immunized with the vWFA2 domain 
of COL7C for induction of experimen-
tal EBA. Mice that presented at least 
2% of body surface area affected by 
blistering were randomly allocated to 
either the ETA or PBS treatment group. 
Compared to PBS-treated controls, mice 
that received ETA showed a clinically 
significantly reduced extent of blistering 
(Figure 5), indicating the important role 
of TNF during the pathogenesis of  
experimental EBA.
DisCUssioN
In this study, we provide evidence for 
a proinflammatory role of TNF in experi-
mental models of a prototypic organ- 
specific autoantibody-mediated disease. 
First, we observed increased TNF expres-
sion in the skin of mice that developed 
experimental EBA and in human BP and 
EBA patients. Second, pharmacological 
blockade of TNF by ETA or a murine 
TNF-blocking mAb, if applied before 
the onset of skin blisters, led to signifi-
cantly milder disease progression in an-
ti-mCOL7C IgG-treated mice compared 
with control mice. Third, in addition to 
this prophylactic treatment, we further 
demonstrated that TNF inhibition ef-
fectively improved already established 
To further investigate the role of TNF 
in the context of AIBDs, the impact of 
ETA with known effectiveness against 
murine TNF was investigated in anti-
body transfer–induced EBA. For this pur-
pose, C57BL6/J mice were treated with 
ETA and subsequently anti-mCOL7C 
IgG. Although all mice developed clin-
ical symptoms of EBA (Figures 3A–D), 
the disease was significantly milder in 
ETA-treated mice compared with the 
control group (d 8, p = 0.03; d 12, p = 0.005; 
Figure 3E). In addition, circulating cyto-
kine levels were evaluated in the serum 
obtained from diseased mice treated 
of infiltrated leukocytes in lesional skin 
obtained from mice with experimental 
EBA (Figure 2J). To further investigate 
this point, we compared monocytes/mac-
rophages based on the possibility of their 
producing reactive ROS after IC stimula-
tion (Supplementary Figure S1A, S1B) and 
inducing split formation after immune 
complex formation in an ex vivo assay 
with human skin (Supplementary  
Figure S1C). Indeed, besides the known 
fact that PMNs contribute to this patho-
genic effect in AIBDs, monocytes/
macrophages are a second cell type that 
directly contributes to blister formation.
Figure 2. Prophylactic TNF blockade reduced the extent of skin disease in antibody transfer– 
induced EBA. Mice injected with rabbit anti-mCOL7C IgG and treated with (A,B) an  
isotype antibody (n = 8) or (C,D) a monoclonal antibody to TNF (TNF mAb, n = 6) 2 d prior 
to initial anti-mCOL7C IgG injection, followed by five treatments every other day until d 8. 
Ears and trunks of isotype-treated mice demonstrated erythema and erosions, while less 
disease was observed in TNF mAb–treated mice. (E) Time course of clinical disease devel-
opment, shown as the percentage of body surface area affected by blistering (*p < 0.05, 
**p < 0.01). Representative ear samples from (F–J) isotype-treated and (K–O) TNF mAb–
treated mice with EBA were analyzed histopathologically and immunologically. By direct 
immunofluorescence microscopy, similar (F,K) IgG and (G,L) C3 deposits were observed 
at the dermal-epidermal junction in both experimental groups. Histopathological analysis 
of lesional skin demonstrated comparable (H,M) dermal-epidermal separation in both 
treatment groups, but (I,N) TNF and (J,O) MOMA-2 were detected to a lesser extent in 
(N,O) TNF mAb–treated mice compared with (I,J) isotype-treated mice. Magnification of 
all sections is 200×.
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disease activity in mice as a therapeutic 
approach. Taken together, these obser-
vations suggest that TNF is significantly 
involved in the effector phase of ex-
perimental EBA. Previously, different 
experimental studies demonstrated that 
TNF treatment was also effective in other 
AIBDs. More specifically, TNF plays a 
role in the acantholytic process in PV 
(32,41), and its expression in serum and 
skin of patients with PV (32,41) and BP 
(42) was increased. Furthermore, case 
reports documented the successful use 
of infliximab and ETA in PV patients 
(28–31), and in mucous membrane pem-
phigoid, the use of ETA was suggested 
for patients not responsive to high-dose 
intravenous immunoglobulins (26,43).  
Interestingly, here we observed increased 
levels of TNF only at the site of inflam-
mation (i.e., the skin), while TNF concen-
trations in the serum were identical in 
mice with or without experimental EBA. 
The reason for unchanged serum TNF 
expression in experimental EBA could be 
either too low concentration in the skin 
to affect serum expression or retention in 
the skin by binding to TNF receptors.
For TNF blockade, we employed 
MP6-XT22, a rat TNF-blocking IgG1 
mAb that neutralizes murine TNF and 
is the standard TNF blocking antibody 
used in murine studies (44). The human 
reagent ETA is a TNFR2-Fc fusion pro-
tein (soluble p75-TNF receptor-human 
IgG1) that is also effective at neutraliz-
ing TNF in mice and humans (44). Both 
compounds exhibited the same inhibi-
tory effect on disease progression when 
applied in our model of antibody trans-
fer–induced EBA. TNF signals via two 
receptors, TNFR1 and TNFR2. In con-
trast to TNFR1, which is ubiquitously 
expressed and mediates proinflamma-
tory processes and cell death, TNFR2 
is found on a limited number of cell 
types, such as cells of the hematopoietic 
lineage, endothelial cells and certain 
cells of the central nervous system 
(45), where it promotes tissue repair, 
angiogenesis and cell survival. TNFR2 
is also involved in several immune dis-
eases and inflammatory processes (10), 
Figure 4. TNF inhibition in antibody transfer–induced EBA was associated with changes in 
serum levels of IL-6, G-CSF and KC. Circulating IL-6, G-CSF and KC levels were evaluated 
in murine serum at d 12 of antibody transfer–induced EBA using Bio-Plex. Statistically sig-
nificant reduction of all three molecules was observed in the serum of mice with blocked 
TNF function (TNF mAb/ETA, n = 6) compared with isotype-treated animals (n = 8; *p < 0.05, 
**p < 0.01).
Figure 3. Prophylactic inhibition of TNF using ETA in antibody transfer–induced EBA and 
BP model reduced disease severity. (A–E) Representative clinical pictures on d 12 after 
injection of mice with rabbit anti-mCOL7C IgG and treatment with (A,B) isotype con-
trol (shared with Figure 2) and (C,D) ETA every other day until d 10 starting 2 d prior to 
the initial anti-mCOL7C IgG injection. Both groups developed erythema and erosions. 
(E) Clinical disease score, shown as the percentage of body surface area affected by 
blistering, was reduced in ETA-treated mice (n = 6) compared to isotype-treated mice 
with EBA (n = 8) at d 8 and d 12. (F) Representative pictures of mouse ears on d 2 after 
injection with rabbit anti-mCOL17 IgG and treatment with PBS or ETA every other day  
starting 2 d prior to anti-mCOL17 IgG injection. (E) Clinical disease score, shown as the 
percentage of ear surface area affected by blistering, was reduced in ETA-treated 
mice (n = 6) compared to isotype-treated mice with EBA (n = 8) at d 2 (*p < 0.05,  
**p < 0.01).
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reduces cell infiltration in different au-
toimmune diseases, such as rheumatoid 
arthritis (48). In addition, it had been 
demonstrated that ETA, in contrast to 
other TNF inhibitors (such as infliximab), 
exerts its effect not by inducing apop-
tosis of macrophages (49) but by phos-
phorylating p38 MAPK and STAT3 and 
reducing complement-dependent lysis 
of macrophages (50). The reduced num-
ber of macrophages observed after use 
of TNF-blocking antibodies in antibody 
transfer–induced EBA may therefore be 
due to reduced infiltration of these cells.
CoNCLUsioN
In conclusion, increased TNF expression 
in the skin of mice with experimental 
EBA suggests that this cytokine may 
be a new potential therapeutic target. 
Furthermore, both ETA and TNF-blocking 
antibody significantly impaired skin 
blistering in a prophylactic setting of 
the antibody transfer–induced model 
of EBA. Moreover, therapeutic inter-
vention of TNF activity was able to 
reduce disease activity in mice with 
fully developed skin lesions. Our results 
suggest blockade of TNF function as a 
new therapeutic approach for the treat-
ment of EBA. In line with the fact that 
antibodies like sCD32, anti-Flightless-1 
homolog, anti–GM-CSF and anti-FcgRIV 
have promising inhibitory effects in 
model systems of pemphigoid diseases, 
we believe that the therapy options 
for these difficult-to-treat autoimmune 
disorders will improve in coming years 
(20,24,51,52).
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cytokine levels of macrophage-released 
cytokines such as IL-6, G-CSF and the 
murine IL-8 equivalent keratinocyte- 
derived chemokine (46,47) were reduced 
in mice with antibody transfer–induced 
EBA after therapy with ETA and/or 
TNF blockade, indicating a disease- 
related effect of macrophages in exper-
imental EBA. To address the question 
of whether this increased number of 
macrophages in the skin of human 
and experimental AIBDs represents a 
bystander effect of tissue inflamma-
tion or actively contributes to disease 
expression, we analyzed the role of 
monocytes/macrophages during ROS 
release and split formation using human 
isolated monocytes. Indeed, here we 
show that isolated monocytes directly 
contribute to mechanisms important in 
the pathogenesis of EBA and other  
pemphigoid diseases.
In accordance with our data, it was 
previously shown that TNF blockade 
which makes it likely to function as the 
major signaling receptor in EBA, thus 
is interesting for therapeutic modula-
tion. However, which receptor primar-
ily contributes to EBA development 
and progression is a subject of future 
research.
Our data indicate a reduced inflam-
matory milieu after TNF blockade that 
may contribute to improvement of skin 
disease. After use of TNF-blocking 
antibodies in antibody transfer–induced 
EBA, we observed strongly reduced 
TNF expression and reduced numbers 
of macrophages (MOMA-2–positive 
cells) in lesional skin. To date, the 
contribution of macrophages to the 
development of skin lesions in EBA, in 
both patients and experimental models, 
has been unclear. Here, we show that 
macrophages constitute a substantial 
percentage of infiltrated leukocytes in 
lesional skin obtained from mice with 
experimental EBA. In addition, serum 
Figure 5. Therapeutic application of ETA improved disease severity in immunization- 
induced EBA. Three to six weeks after B6.S mice were immunized with mCOL7C-GST in  
TiterMax, mice developed clinical disease with more than 2% affected skin and were  
allocated into either the PBS (n = 7) or ETA (n = 8) treatment group. Representative clinical 
pictures of mice at 6 wks of treatment that received (A,B) PBS or (C,D) ETA every second 
day for 6 wks. (E) Time course of clinical disease development, shown as percentage 
of body surface area affected by blistering and (F) as area under the curve calculated 
over time for the entire treatment period of 6 wks (*p < 0.05, **p < 0.01).
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